Press release
Pulmonary Arterial Hypertension Pipeline Expands Globally with 55+ Active Therapies in Development, Highlights DelveInsight's Market Intelligence Report
Pulmonary Arterial Hypertension Pipeline
According to DelveInsight, the global Pulmonary Arterial Hypertension (PAH) pipeline features more than 55 prominent companies actively advancing over 55 therapeutic candidates. The analysis comprehensively reviews clinical trials, therapeutic approaches, mechanisms of action, routes of administration, and recent developments shaping the PAH landscape.
The "Pulmonary Arterial Hypertension Pipeline Insight, 2026" report from DelveInsight delivers an in-depth evaluation of the current clinical development environment and future growth opportunities within the PAH market.
This PAH pipeline study provides a detailed commercial and clinical evaluation of drug candidates, spanning from preclinical research to marketed products. It also includes extensive drug profiles covering mechanisms of action, clinical trial progress, NDA approvals (where applicable), and development activities such as technological advancements, collaborations, mergers and acquisitions, funding events, regulatory designations, and other product-specific updates.
Request for free sample report @ Pulmonary Arterial Hypertension Pipeline Insight [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Major Highlights from the Pulmonary Arterial Hypertension Pipeline Report:
* Companies worldwide are consistently pursuing innovative PAH therapies, achieving notable progress in recent years.
* Leading pharmaceutical and biotech firms-including Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Sciences, Acceleron Pharma, Eiger BioPharmaceuticals, and AstraZeneca-are actively developing next-generation PAH treatments.
* Promising investigational therapies progressing through various trial phases include AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab, Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, ubenimex, Olaparib, and others, all of which are expected to influence the PAH treatment landscape in the years ahead.
* In December 2025, tiakis Biotech AG announced completion of a comprehensive data package supporting advancement of Tiprelestat into a Phase II clinical trial for PAH following successful preclinical GLP-tox studies. Tiprelestat, a first-in-class biological neutrophil elastase inhibitor and BMPR2 amplifier, is being developed as a disease-modifying treatment aimed at reducing inflammation and reversing vascular remodeling associated with PAH.
* In November 2025, Inhibikase Therapeutics, Inc. (Nasdaq: IKT) revealed plans to initiate a global pivotal Phase III trial for IKT-001 under the IMPROVE-PAH study, anticipated to commence in early 2026.
* Also in November 2025, Cereno Scientific sought FDA clearance to launch a global clinical study evaluating its oral candidate CS1, a repurposed seizure medication, in PAH patients. If approved, the Phase IIb placebo-controlled trial is expected to begin in the first half of 2026 in collaboration with a global CRO.
* In September 2025, AllRock Bio Inc. secured $50 million in Series A funding co-led by Versant Ventures and Westlake BioPartners to advance ROC-101, an oral pan-ROCK inhibitor licensed from Sanofi, into Phase II development for PAH and ILD-PH.
* In August 2025, VASTHERA Co., Ltd. received FDA IND clearance to begin a Phase I study of VTB-10, a first-in-class Chemzyme designed to mimic peroxiredoxin function and address oxidative stress in PAH lesions.
* In March 2025, Merck (NYSE: MRK), operating as MSD outside North America, released Phase III ZENITH trial results for WINREVAIR Trademark (sotatercept-csrk), demonstrating a 76% relative risk reduction in major morbidity and mortality events compared to placebo among high-risk PAH patients.
* Earlier, in January 2025, Merck shared preliminary findings from the same Phase III ZENITH study, reinforcing the significant clinical benefit of WINREVAIR in WHO functional class III/IV PAH patients.
* In October 2024, Inhibikase Therapeutics, Inc. completed a $110 million private placement to fund its Phase IIb '702' trial in PAH and support broader corporate initiatives.
Pulmonary Arterial Hypertension Overview
Pulmonary Arterial Hypertension is an uncommon, progressive disorder characterized by elevated blood pressure within the pulmonary arteries. This increased vascular pressure places strain on the right ventricle, leading to symptoms such as dyspnea, fatigue, chest discomfort, and peripheral edema. PAH may arise idiopathically, genetically, or secondary to other medical conditions including connective tissue diseases or congenital heart abnormalities. Although curative treatments are not yet available, current management strategies-including pharmacotherapy, oxygen supplementation, and lifestyle modification-can alleviate symptoms and improve patient outcomes.
Get a Free Sample PDF Report to know more about Pulmonary Arterial Hypertension Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight [https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Pulmonary Arterial Hypertension Emerging Drugs in Development
Innovative PAH therapies under investigation across clinical phases include:
* TYVASO/TYVASO DPI/TREPROST Inhalation Solution (treprostinil): United Therapeutics/Mochida Pharmaceutical
* OPSYNVI/YUVANCI (macitentan and tadalafil): Johnson & Johnson
* WINREVAIR (sotatercept): Merck
* UPTRAVI (selexipag): Johnson & Johnson/ Nippon Shinyaku
* AV-101: Aerovate Therapeutics
* LTP001: Novartis
* KER-012: Keros Therapeutics
* TPN171H: Vigonvita Life Sciences
* Treprostinil Palmitil: Insmed Incorporated
* Satralizumab (Genetical Recombination): Chugai Pharmaceutical
* Sotatercept: Merck Sharp & Dohme
* Macitentan: Janssen Pharmaceutical
* ACT-293987: Actelion
* GB002 (seralutinib): Gossamer Bio
* Parenteral Treprostinil: Lung Biotechnology PBC
* Ralinepag: United Therapeutics
* Selonsertib: Gilead Sciences
* Sotatercept: Acceleron Pharma
* ubenimex: Eiger BioPharmaceuticals
* Olaparib: AstraZeneca
Further Pulmonary Arterial Hypertension product details are provided in the report. Download the Pulmonary Arterial Hypertension pipeline report to learn more about the emerging Pulmonary Arterial Hypertension therapies [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Pulmonary Arterial Hypertension Route of Administration & Molecule Classification
The PAH pipeline is categorized by multiple routes of administration, including oral, parenteral, intravitreal, subretinal, and topical delivery systems.
Therapies are further segmented by molecular type, such as monoclonal antibodies, peptides, polymers, small molecules, and gene therapies.
Pulmonary Arterial Hypertension Pipeline Segmentation
The report evaluates over 55 pipeline assets across:
* Phase III (late-stage)
* Phase II (mid-stage)
* Phase I (early-stage)
* Preclinical and discovery stages
* Discontinued or inactive programs
Pulmonary Arterial Hypertension Market Drivers
* Increasing global prevalence of PAH
* Strong and expanding therapeutic pipeline
* Novel drug combinations entering development
Pulmonary Arterial Hypertension Market Barriers
* High treatment costs
* Limited awareness in developing regions
* Access and reimbursement challenges
Request for Sample PDF Report for Pulmonary Arterial Hypertension Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Scope of Pulmonary Arterial Hypertension Pipeline Drug Insight
* Coverage: Global
* Key Pulmonary Arterial Hypertension Companies: Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Science, Acceleron Pharma, Eiger BioPharmaceuticals, AstraZeneca, and others
* Key Pulmonary Arterial Hypertension Therapies: AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab (Genetical Recombination), Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, Sotatercept, ubenimex, Olaparib, and others
* Pulmonary Arterial Hypertension Therapeutic Assessment: Pulmonary Arterial Hypertension current marketed and Pulmonary Arterial Hypertension emerging therapies
* Pulmonary Arterial Hypertension Market Dynamics: Pulmonary Arterial Hypertension market drivers and Pulmonary Arterial Hypertension market barriers
Request for Sample PDF Report for Pulmonary Arterial Hypertension Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
1. Pulmonary Arterial Hypertension Report Introduction
2. Pulmonary Arterial Hypertension Executive Summary
3. Pulmonary Arterial Hypertension Overview
4. Pulmonary Arterial Hypertension- Analytical Perspective In-depth Commercial Assessment
5. Pulmonary Arterial Hypertension Pipeline Therapeutics
6. Pulmonary Arterial Hypertension Late Stage Products (Phase II/III)
7. Pulmonary Arterial Hypertension Mid Stage Products (Phase II)
8. Pulmonary Arterial Hypertension Early Stage Products (Phase I)
9. Pulmonary Arterial Hypertension Preclinical Stage Products
10. Pulmonary Arterial Hypertension Therapeutics Assessment
11. Pulmonary Arterial Hypertension Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Pulmonary Arterial Hypertension Key Companies
14. Pulmonary Arterial Hypertension Key Products
15. Pulmonary Arterial Hypertension Unmet Needs
16 . Pulmonary Arterial Hypertension Market Drivers and Barriers
17. Pulmonary Arterial Hypertension Future Perspectives and Conclusion
18. Pulmonary Arterial Hypertension Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pulmonary-arterial-hypertension-pipeline-expands-globally-with-55-active-therapies-in-development-highlights-delveinsights-market-intelligence-report]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Arterial Hypertension Pipeline Expands Globally with 55+ Active Therapies in Development, Highlights DelveInsight's Market Intelligence Report here
News-ID: 4403764 • Views: …
More Releases from ABNewswire
Freshness From the Shadows: NecroBrew Proves That Roasted-to-Order Coffee and Al …
NecroBrew is challenging the conventions of specialty coffee with a roasted-to-order model wrapped in a bold alternative identity. The brand has found a growing audience among coffee lovers who demand peak freshness and refuse to settle for bland branding.
The journey from green coffee bean to finished cup is one that hinges on timing. Roast too far in advance and the nuanced flavors that make specialty coffee special begin to fade.…
She Survived Cancer. The Harder Challenge Was Learning to Live Again
I CAN-CER VIVE follows Monya Williams' journey through trauma, illness, and the search for joy after survival
MARIETTA, GA - Surviving cancer is often seen as the end of a difficult journey. For Monya Williams, it marked the beginning of a new one.
Years before she was diagnosed with breast cancer at age forty-six, Williams was carrying wounds that few people could see. She survived sexual, physical, and emotional abuse during childhood…
Ideal Wellness Addresses Chronic Fatigue in Baltimore Through Physician-Led IV N …
Ideal Wellness in Baltimore, MD, provides structured IV therapy for chronic fatigue to address nutritional depletions, mitochondrial disruptions, and metabolic imbalances. Led by clinic director Jamie Taylor, the practice utilizes individualized IV nutrient formulations based on unique clinical profiles rather than standardized menus. This physician-guided, non-pharmaceutical approach offers a targeted pathway for local residents seeking functional recovery.
BALTIMORE, MD - Ideal Wellness [https://idealwellnessmd.com/], an integrative health clinic based in Baltimore, MD,…
Wireless Charger Manufacturer WeCent Launches X40 Mini 3-in-1 Magnetic Charging …
WeCent, a manufacturer specializing in GaN and wireless charging solutions, has introduced the X40 Mini 3-in-1 Magnetic Charging Stand [https://www.gdwecent.com/product/x40-mini-3-in-1-magnetic-charging-stand/], a compact foldable charger designed for smartphones, smartwatches, and wireless earbuds. Available in a Cosmic Orange finish, the new model supports MagSafe-compatible iPhones, Apple Watch, AirPods, Samsung, Huawei, and other Qi-enabled devices, offering versatile charging across multiple device ecosystems.
The X40 Mini expands WeCent's wireless charging portfolio with a focus on…
More Releases for Pulmonary
Innovation In Pulmonary Drug Delivery Devices Industry Trends Gaining Momentum i …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pulmonary Drug Delivery Devices Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pulmonary drug delivery devices has experienced significant growth in the past few years. The market is projected to increase from $49.52 billion in 2024 to $52.8 billion in 2025,…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
